In the development of the drug Zeqmelit/ISICORT[®], AcuCort has managed to combine the benefits of the well-proven substance dexamethasone and the patented user-friendly oral film for quick availability and relief in emergency situations such as severe and acute allergic reactions.

The drug was recently approved in Denmark under the name Zeqmelit and has previously been approved in Sweden under the brand name ISICORT[®]. The registration process for Finland is ongoing and intensive work is underway on registration applications for other priority markets. AcuCort's goal is to commercialize Zeqmelit/ISICORT® globally, i.e. in the EU, the US and in selected key markets.

"We are very pleased that AcuCort has passed another important milestone as Zeqmelit is now approved in Norway. The fact that the company's first innovative drug is approved throughout Scandinavia creates good conditions for a positive development of the company. I am optimistic about the upcoming commercialization and our continued growth journey," says Jonas Jönmark, CEO of AcuCort.

This information is information that AcuCort AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person below, on September 27, 2022.